The global infusion pharmacy management market was valued at around US$ 7,872.0 Million at the end of 2021. The market is projected to register a 5.40% CAGR and top a valuation of US$ 14,053.52 Million by 2032.
Increasing prevalence of chronic disorders such as gastrointestinal diseases, cancer, diabetes and pain related disorders are the key factors responsible for markets’ growth.
The injection of medications or medicine through a sterile catheter or needle is known as infusion treatment. A qualified healthcare provider regularly inserts them and secures them in the patient's vein. Only patients who do not respond to oral treatment and whose health has not yet improved are typically recommended this therapy. Pain management medications, antibiotics, antiviral, antifungal, and nutritional pharmaceuticals are infused into the patient's body at the infusion pharmacy using a needle or catheter. The infusion medication system is used to treat a variety of diseases including cancer, gastrointestinal disorders, diabetes, and diseases related to pain.
Infusion therapy was previously only provided in hospitals, but it is now also available in outpatient infusion therapy facilities and even in patients' homes. Because it takes more qualified nurses, home infusion pharmacy management is more expensive than hospital infusion pharmacy administration. The state board of pharmacies has granted that these nurses are licencesed and permitted after confirming that they adhere to the stringent criteria and rules established by the board and the government. Both the public and private insurance programmes are integrated with the infusion pharmacy management.
| Attributes | Details |
| Infusion Pharmacy Management Market Value in 2021 | US$ 7,872.0 Million |
| Infusion Pharmacy Management Market Value in 2032 | US$ 14,053.52 Million |
| Infusion Pharmacy Management Market CAGR (2022 to 2032) | 5.40% |
Oral medication should not be used as often as infusion medication, which is more effective and is anticipated to drive market expansion. More personalized treatment options, more extended time of medication efficacy, and higher absorption rate that oral medication are some the advantages of infusion medication over others, which is supposed to boost the market’s growth.
Additionally, the pharmaceutical industry's numerous initiatives to improve healthcare infrastructure and enhance technology will encourage the infusion pharmacy management market to expand rapidly.
Moreover, in 2018, 18.1 million new cases of cancer were reported worldwide, according to the WHO. Another significant disease group that necessitates the use of infusion equipment is diabetes. By 2030, the WHO predicts that the disease will rank as the seventh largest cause of mortality. Numerous cancer treatments are now available, which has greatly increased number of cancer survivors. According to the WHO, there are around 43.8 million people worldwide who are still alive five years after being given a cancer diagnosis. Thus, it is anticipated that the market will profit from the rising popularity of home-based cancer therapy in the next years due to its benefits, such as cost-effectiveness.
The infusion pharmacy management market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America dominated the regional infusion pharmacy management market due to USA region, as the region top suppliers’ controls almost half of the market in United States. Option Care and BioScrip are the two largest key players in the United States. Additionally, for instance, in 2019, Option Care merged with BioScrip to offer the ability to completely reinvent the infusion care experience and provide high-quality care on a nationwide scale at lower costs.
Moreover, Europe is supposed to grow fastest over the projection period due to growing prevalence of chronic disorders such as diabetes and cardiovascular diseases. For instance, in 2021, according to International Diabetes Federation, around 61 million adults around 20-79 years were suffering from diabetes in Europe region.
Managed Health Care Associates, Inc., Southside Group of Companies, ContinuumRx, Cigna, ARJ Infusion Services, CareCentrix, Inc., MedicoRx, Mediware, OptumRx, Healix, CVS Health, BioScrip, BD, Option Care, and McKesson.
| Report Attributes | Details |
| Growth Rate | CAGR of 5.40% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The global infusion pharmacy management market is anticipated to register a CAGR of 5.40% during the forecast period.
Managed Health Care Associates, Inc., Southside Group of Companies, ContinuumRx, Cigna, ARJ Infusion Services, CareCentrix, Inc., MedicoRx, Mediware, OptumRx, Healix, CVS Health, BioScrip, BD, Option Care, and McKesson., among others are some prominent infusion pharmacy management market players.
Explore Similar Insights
Infusion Pharmacy Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
